T
Terremoto Biosciences
Delivers superior small molecule medicines with enhanced therapeutic benefit
About Terremoto Biosciences
Terremoto Biosciences is a pioneering startup operating in the pharmaceutical industry, specifically in the drug development sector. The company is revolutionizing the field with its innovative covalent chemistry approach. In simpler terms, they are developing new drugs using a unique method that involves creating strong bonds between molecules, which can lead to more effective medicines.
Read full description
Historically, covalent medicines have targeted a specific amino acid called cysteine. Terremoto Biosciences, however, is leveraging a different amino acid, lysine, to expand the range of potential drug targets. This could not only broaden the scope of diseases that can be treated but also enhance the efficacy of existing medicines.
The company's business model revolves around the research, development, and commercialization of these novel covalent medicines. Their revenue is likely to be generated from the sales of these drugs once they have been successfully developed and approved for use.
Terremoto Biosciences serves a broad range of clients, primarily within the healthcare sector. These could include hospitals, clinics, and other healthcare providers, as well as patients in need of their innovative treatments.
The company prides itself on its inclusive culture of excellence, seeking a diverse team of chemists, biologists, and industry-leading drug developers. Their commitment to innovation and excellence is reflected in their tenacious work ethic, inventive scientific approach, and unwavering drive to deliver superior therapeutics to patients.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- San Francisco, United States
- Employees
- 52
- Open positions
- 1
- Dealroom signal
- 63.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Biotechnology, Spinout, Rumoured $1B, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES COther financing | Apr 2026 | $108M | $875M | Cormorant Asset Management · RA Capital Management · BeOne Medicines · Deep Track Capital | ↗ |
| SERIES BOther financing | Nov 2023 | $175M | $700M | Third Rock Ventures · Novo Holdings · EcoR1 Capital · Cormorant Capital | ↗ |
Growth signals
Latest recorded traffic for Terremoto Biosciences is 5K monthly website visits, up 19% over the last three months. Terremoto Biosciences's team declined 18.8% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A5 investors entered at this stage
OrbiMed
Third Rock Ventures
Novo Holdings
EcoR1 Capital- CCCormorant Capital
Series B and later5 investors entered at this stage
Cormorant Asset Management
RA Capital Management
BeOne Medicines
Deep Track Capital
Osage University Partners
Other known investors1 additional known investor
University of California, San Francisco
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Terremoto Biosciences on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Terremoto Biosciences’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.